Cytokinetics (CYTK) Total Current Liabilities (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Total Current Liabilities of $199.2 million for Q1 2026, up 24.7% year-over-year from $159.7 million in Q1 2025, and down 1.61% quarter-over-quarter from $202.5 million in Q4 2025.
Cytokinetics (CYTK) Total Current Liabilities (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Total Current Liabilities for 17 consecutive years, with $199.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 24.7% year-over-year to $199.2 million; the TTM figure through Mar 2026 stood at $199.2 million (up 24.7% YoY), while the FY2025 annual figure was $202.5 million, up 12.68% from the prior year.
- Total Current Liabilities eased to $199.2 million in Q1 2026 per CYTK's latest filing, from $202.5 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $202.5 million in Q4 2025 and bottomed at $65.6 million in Q2 2023.
- Historically, Total Current Liabilities has averaged $113.6 million across 5 years, with a median of $102.7 million in 2023.
- On a YoY basis, Total Current Liabilities climbed as much as 86.05% in 2022 and fell as far as 5.41% in 2022.
- Cytokinetics' Total Current Liabilities stood at $84.6 million in 2022, then climbed by 21.34% to $102.7 million in 2023, then jumped by 74.99% to $179.7 million in 2024, then advanced by 12.68% to $202.5 million in 2025, then fell by 1.61% to $199.2 million in 2026.
- Business Quant data shows CYTK's Total Current Liabilities at $199.2 million in Q1 2026, $202.5 million in Q4 2025, and $142.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 181.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 181.43 Mn |
| Mar 31, 2026 | 199.19 Mn |
| Dec 31, 2025 | 202.45 Mn |
| Sep 30, 2025 | 142.14 Mn |
| Jun 30, 2025 | 131.06 Mn |
| Mar 31, 2025 | 159.73 Mn |
| Dec 31, 2024 | 179.67 Mn |
| Sep 30, 2024 | 109.81 Mn |
| Jun 30, 2024 | 102.78 Mn |
| Mar 31, 2024 | 88.86 Mn |
| Dec 31, 2023 | 102.68 Mn |
| Sep 30, 2023 | 77.72 Mn |
| Jun 30, 2023 | 65.62 Mn |
| Mar 31, 2023 | 75.22 Mn |
| Dec 31, 2022 | 84.62 Mn |
| Sep 30, 2022 | 76.50 Mn |
| Jun 30, 2022 | 66.84 Mn |
| Mar 31, 2022 | 66.85 Mn |
| Dec 31, 2021 | 71.86 Mn |
| Sep 30, 2021 | 80.87 Mn |